1 / 66

Introduction to Teleporting to Seattle: Advances in Transplant Immunosuppression

Introduction to Teleporting to Seattle: Advances in Transplant Immunosuppression. Why is this program important?. Cumulative Allograft Failure and Yearly Attrition Rates for First Kidney Transplants. New Insights Into Improving Patient Outcomes.

yvette-salas
Download Presentation

Introduction to Teleporting to Seattle: Advances in Transplant Immunosuppression

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction to Teleporting to Seattle: Advances in Transplant Immunosuppression

  2. Why is this program important?

  3. Cumulative Allograft Failure and Yearly Attrition Rates for First Kidney Transplants

  4. New Insights Into Improving Patient Outcomes

  5. Robert Montgomery, MD, PhD, Johns Hopkins University

  6. Robert Gaston, MD, University of Alabama, Birmingham

  7. Dr. Fuad Shihab, University of Utah

  8. Angela Webster, MBBS, MS, PhD, University of Sydney

  9. David Cronin, MD, PhD, Medical College of Wisconsin

  10. Please Note

  11. Acute and Chronic Antibody-Mediated Rejection in Kidney Transplantation

  12. Acute AMR*Banff 97 Diagnostic Categories for Renal Allograft Biopsies  Banff ’09 Update

  13. Early AMR Portends Worse Long-term Renal Allograft and Patient Survival

  14. Detection of Anti-HLA Class I but Not C1q-Fixing DSAs Before Kidney Transplantation Predicts Early Allograft Loss

  15. Progression of Pathologic Changes in Kidney Allografts of HLA-Incompatible Transplant Recipients

  16. Chronic Active AMR*Banff 97 Diagnostic Categories for Renal Allograft Biopsies  Banff ’09 Update

  17. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment

  18. Effectiveness of Rituximab and IVIG for the Treatment of Chronic AMR in KT Recipients

  19. Summary

  20. Late Kidney Allograft Dysfunction

  21. Alloimmune and Nonalloimmune Kidney Graft Losses: Improving Our Understanding of Factors Associated with Failure

  22. Long-term Outcomes Following Acute Rejection in KT Recipients: an ANZDATA Analysis

  23. Early AR Initiates Alloimmune Mechanisms, Ultimately Leading to Kidney Allograft Failure

  24. Histology 1-Year Post-KT Relates to Risk of Alloimmune-Mediated Allograft Failure Long-term

  25. Potential Importance of 3-Year Surveillance Biopsies in Renal Transplantation

  26. DeKAF Pathology Clusters: Follow-up at 5 Years

  27. DR+, DQ, or High-Level DR Alone Associated De Novo Donor-Specific HLA Antibodies Are Strong Predictors of Biopsy-Proven Chronic AMR Before Appearing Clinical Renal Damage After Renal Transplantation

  28. Soluble BAFF Levels Correlate With De Novo DSA Development and Progression to Chronic Active AMR in Pediatric Recipients of First Kidney Transplants

  29. APOL1 and MHY9 Gene Variants and Allograft Outcomes in Kidney Transplantation

  30. SHROOM3 Is a Predictor of Fibrosis in CAN and CKD

  31. High Creatinine and Advanced Chronic Rejection Predicts Allograft Loss in Nonadherent KT Recipients

  32. Summary

  33. Conversion Strategies for CNI Sparing in Kidney Transplantation

  34. Efficacy and Safety of 3 Different Treatment Regimens in Patients With De Novo Renal Transplant: Follow-up Results of the HERAKLES Trial at Month 24

  35. Superior Renal Function in an EVL-Based, CNI-Free Regimen Compared With Standard CsA/MMF and Low CsA/EVL: Follow-up of the HERAKLES Study at Month 24

  36. Outcome on Renal Function of an EVL-Based Therapy After CNI Withdrawal in Maintenance Renal Transplant Recipients: 4-Year Data From the APOLLO Trial

  37. Improved Renal Function of an EVL/EC-MPS Regimen After CNI Withdrawal in Patients With De Novo Renal Transplant: 5-Year Follow-up of the ZEUS Trial

  38. Long-Term Assessment of Function in Patients Completing the Spare-the-Nephron Study With a Functioning Graft

  39. Conversion From TAC- to SRL-Based Immunosuppressive Regimen in KT Recipients: 2-Year Results

  40. Prospective and Randomized Trial Comparing TAC vs SRL After Simultaneous PKT

  41. New-Onset Proteinuria After Conversion to SRL in Renal Transplantation

  42. Outcomes of Switching to Belatacept from CNI in KT Recipients: 3-Year Results from the Long-term Extension of a Phase 2 Study

  43. Conversion to an SRL-Based Regimen Is Associated With Lower Incidence and Faster Resolution of BK Viremia in Low-Risk KT Recipients

  44. Malignancy After Solid Organ Transplantation

  45. Can the Risk of Cancer Transmission From Organ Donors Be Eliminated?

  46. Death on Waiting List and Risk for Transmission of Cancer: Where Is the Right Balance?

  47. Risk for Transmission of Cancer From Solid Organ Donors in the United States

  48. Risk for Recurrence of Preexisting Cancer in Organ Recipients

  49. Association Between De Novo Posttransplant NMSC and Solid Tumor After SOT: An Analysis of OPTN/UNOS Data

  50. Occurrence of NMSC Predicts Risk for Subsequent Solid Organ Cancer

More Related